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The presence of cardiovascular co-morbidities and the known effects of coronaviruses on the 
cardiovascular system have called attention to the pot ntial implications for patients with 
cardiovascular risk factors. This evidence-based viwpoint will address two questions: (a) are 
individuals with underlying cardiovascular risk factors (e.g. high blood pressure or diabetes) 
or overt disease (e.g. coronary heart disease, heart failu e, kidney disease) more likely to 
develop severe Covid-19 and to die than those without underlying conditions? (b) does the 
regular use of angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin-receptor 
blockers (ARB) make patients more likely to get infected and to die of Covid-19?  
 
With a necessary cautionary note that the evidence around the links between Covid-19 and 
cardiovascular disease is accruing at a fast pace, to date we can conclude that: (a) the greater 
susceptibility of individuals with underlying cardiovascular conditions to develop more 
severe Covid-19 with higher mortality rate is likely to be confounded, in part, by age and the 
type of co-morbidities. Patients with heart failure or chronic kidney disease might show an 
excess risk; (b) neither ACE-i nor ARB are associated with greater risk of SARS-Cov2 
infection, or severity or risk of death in patients with Covid-19. Patients on these drugs 
should not stop them, unless under strict medical supervision and with the addition of a 





As of 14 May 2020, there have been 4,369,410 confirmed cases of Novel Coronavirus 
Disease 2019 (Covid-19) due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) infection in the world, with 297,569 fatalities globally1. The epidemic originated in 
the Wuhan, Hubei province of China, and spread rapidly throughout mainland China and 
worldwide, reaching pandemic proportions2. The clinical manifestations initially were of a 
viral pneumonia with fever, cough, fatigue and dyspnoea2-3, severe acute respiratory 
syndrome (ARDS) some requiring hospitalisation, with escalation to intensive care support 
with oxygen, mechanical ventilation and, eventually, death. The rapid dissemination of the 
pandemic trough Asia, Europe and North America has revealed additional patterns of 
presentation features, comorbidities and factors associated with mortality3. The presence of 
cardiovascular (CV) co-morbidities and the known effects of coronaviruses on the CV system 
have called attention to the potential implications for patients with CV risk factors4.  
 
This evidence-based viewpoint will attempt to answer t o questions: (a) are individuals with 
underlying cardiovascular risk factors (e.g. high blood pressure or diabetes) or overt disease 
(e.g. coronary heart disease, heart failure, kidney disease) more likely to develop severe 
Covid-19 and to die than those without underlying conditions? (b) does the regular use of 
angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin-receptor blockers (ARB) 
make patients more likely to get infected and to die of Covid-19? 
 
Covid-19 and underlying CV risk. 
The most common comorbidities among patients admitted to hospitals worldwide have been 
hypertension and diabetes, followed by cardiovascular and respiratory diseases2-5. Table 1 
summarises the prevalence of hypertension and diabetes r corded in 18 reports (10 from 
China2, 6-9, 14, 16-21, 3 from USA5, 13, 15, 2 from Italy10-11 and 1 from a multicentre study from 3 
continents12) and, where available, the severity and mortality in hospitalised patients with 
confirmed Covid-19 by underlying risk factors. The reported prevalence of pre-existing 
hypertension varied from 12.2%14 to 78.6%13, and the prevalence of pre-existing diabetes 
varied from 7.4%2 to 38.2%13. Furthermore, some studies reported an increased severity of 
symptoms in hospitalised patients with confirmed Covid-19 and underlying hypertension or 
diabetes, with a 2.7 and 3.8 folds higher severity17 and with a fatality ratio up to 2.6 and 4.4 
folds2, respectively (Table 1). A meta-analysis of 2,552 confirmed Covid-19 patients from 11 
studies suggested that the severity of Covid-19 was higher in the presence of hypertension 
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(pooled unadjusted OR 2.49, 95% CI 1.98 to 3.12)22. Similarly, a meta-analysis of 6,452 
patients with Covid-19 from 30 studies showed that pre-existing diabetes was associated with 
poor outcome including severity of Covid-19 (unadjusted risk ratio 2.45, 95% CI 1.79 to 
3.35) and mortality (unadjusted risk ratio 2.12, 1.44 to 3.11)23. Meta-regression indicated age 
and hypertension as the statistically significant explanatory variables of such associations.  
 
Are these early figures a reflection of a true causal link between the presence of these risk 
factors and both the propensity to acquire the infection and the prospect of a worse outcome? 
In the case series of 1,099 patients with confirmed Covid-19 admitted to 552 hospitals in 
mainland China, 15% had hypertension and 7% had diabetes2.  Covid-19 was twice as severe 
in them and the mortality was almost three times as high. In a larger multi-centre case series 
of 5,700 patients with Covid-19 admitted to 12 hospitals New York City, Long Island and 
Westchester County in the USA, the prevalence was much higher, with one in two patients 
with hypertension and a third of them with diabetes4. Finally, a large study of 7,337 
confirmed cases of Covid-19 patients admitted to 19 hospitals in the Hubei Province of China 
between 30 December 2019 and 20 March 2020, of whom 952 had type 2 diabetes, reported a 
28-days greater mortality from Covid-19 in people with diabetes compared to non-diabetics 
(7.8% vs 2.7%)21. The association was independent of age, sex and severity of Covid-19 (HR 
1.49; 95% CI 1.13 to 1.96). However, no further adjustments were made for concomitant 
comorbidities.  
 
The groups with more comorbidities and worse outcomes were, as one would expect in an 
unselected population, older that the groups with fewer comorbidities and better outcome. 
The majority of the case series reported unadjusted results for either age or presence of 
comorbidities (Table 1). Covid-19 case fatality rates and CV risk both increase with age and 
with the presence of concomitant comorbidities, so that the association between Covid-19 
and CV risk factors might reflect the confounding effect of these variables. More recently, a 
large study of 8,910 hospitalised patients with Covid-19 from 169 hospitals in North 
America, Europe and Asia confirmed in a multivariate nalysis that significant ‘independent’ 
predictors of in-hospital death, in addition to age >65 years, are presence of coronary heart 
disease, heart failure, cardiac arrhythmias, COPD, current smoking, but not hypertension or 
diabetes13. Similarly, a smaller study from Italy confirmed age, heart failure and chronic 
kidney disease (but not hypertension and diabetes) as independent predictors of death in 
hospitalised Covid-19 patients11. Finally, a meta-regression analysis of the associati n 
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between diabetes and severity and outcome of Covid-19 indicated that the association was 
explained primarily by age and concomitant presence of hypertension23. Further analyses of 
incoming data will undoubtedly refine our understanding of the interplay between underlying 
cardiovascular risk and Covid-19. 
 
Is there any plausible explanation for the potential increased susceptibility to SARS-CoV-2 
infection and the excess risk of death from Covid-19 of patients with underlying CV disease? 
Severe infections are recognised triggers for CV disease expression24, increasing the 
incidence, severity and mortality from infectious di eases25.  Numerous mechanisms have 
been suggested that would explain an increased risk of CV disease4, 26. They include vascular 
endothelial cell dysfunction, myocardial depression, stress cardiomyopathy, myocarditis and 
arrhythmias, coagulopathies and thrombosis. Early predictive markers of severity and worse 
prognosis in Covid-19 patients have been detected in raised levels of high-sensitivity cardiac 
troponin I (hs-TnI) levels18 and high D-dimer levels on admission20. 
 
Covid-19 and the renin-angiotensin-aldosterone system 
The interactions between Coronaviruses (SARS-CoV-1, MERS-CoV and SARS-Cov-2) and 
the renin-angiotensin-aldosterone system (RAAS), via the angiotensin-converting enzyme 2 
(ACE2), have been postulated to modulate the infectivity of these viruses and to influence the 
prognosis of the ensuing respiratory diseases27-28  
 
Unlike ACE, ACE2 does not convert Ang I to Ang II, nor do ACE inhibitors (ACE-i) block 
its activity29. The primary substrate of ACE2 is Angiotensin II (Ang II) that is converted to 
Ang (1-7), thereby attenuating its effects on vasoconstriction, sodium retention and fibrosis 
(Figure 1). ACE2 also converts Angiotensin I to Ang (1-9). ACE2 is primarily a membrane-
bound enzyme, and its soluble circulating levels in the blood are very low. Membrane-bound 
ACE2 has been identified as a functional receptor for coronaviruses29-30. The spike protein of 
the virus binds to the membrane ACE2, highly expressed in lungs and heart, acting as a 
carrier for the entry (endocytosis) of the virus into the cell and its replication27-28. Ang II 
activation of AT1 receptors (type 1) increases soluble ACE2 levels by cleaving the anchoring 
of ACE2 to the cell membrane (shedding). SARS-CoV-2 bound to soluble ACE2 is, then, 
kept in solution and prevented from entering the cells29-30. Theoretically, ACE-i, might 
reduce the shedding of membrane ACE2, increasing the chance of SARS-CoV-2 binding and 
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endocytosis. Conversely, ARB would increase shedding of ACE2, increasing the amount of 
soluble ACE2 to which SARS-CoV-2 would bind and kept soluble (not entering the cell)29-30.  
 
Is there evidence that the use of ACE-i and ARB increase susceptibility to infection by 
SARS-CoV-2 and worsen the prognosis of patients with Covid-19? Patients with 
hypertension and diabetes have been seen to experienc  a high case-fatality rate. This 
observation has led to concerns about the safety and the potential effects of therapies that 
block the RAAS31, commonly used in patients with hypertension, diabetes, heart failure and 
other CV conditions in which they are indicated. This t eory, without direct evidence in 
support, has led to dangerous calls by some to advise patients to stop ACE-i and ARB 
therapies32. Table 2 summarises the studies to date that have addressed these questions with 
different study designs and in different case-serie. All, but one10, are retrospective case-
series or observational studies of hospitalised patients with confirmed Covid-19 or positivity 
to SARS-CoV-2 infection. Two of them were in hypertensive patients only14,34. In all of them 
the results indicate, with different degree of confidence, that neither the use of ACE-i and/or 
ARB are associated with a greater risk of infection fr m SARS-CoV-2, or of severity or 
death in Covid-19 patients. A separate mention is necessary for a population-based case-
control study carried out in the Lombardy region of Italy, one of the hardest hit by the 
pandemic in Europe10. In this study 6,272 cases of SARS-CoV-2 infection c firmed 
between 21 February and 11 March 2020 identified through the Regional Health Authority 
register were matched by sex, age and municipality (1:5) with 30,759 controls registered with 
the same Health Authority. All were aged 40 years or older. Information on selected drug use 
and patients’ clinical characteristics were obtained from the Regional Healthcare database on 
healthcare utilisation. More than half of the selected participants had high blood pressure. In 
this highly controlled comparison, the use of ACE-i and ARB did not show any association 
with Covid-19 prevalence, severity or fatality, and no sex difference. Finally, in two studies 
there was a suggestion that the treatment with ACE-i/ARB would be associated with a lower 
rate of severity14 or mortality34. This proposition, whilst highly speculative, finds some 
theoretical corroboration in a possible down-regulation of ACE2 activity in the lungs and 







Can we formulate evidence-based answers to the questions et in the introduction? With a 
necessary cautionary note that the evidence around the links between Covid-19 and CV 
disease is accruing at a fast pace, to date we can conclude that:  
(a) the greater susceptibility of individuals with underlying CV risk factors or overt 
disease to develop more severe Covid-19 with higher mortality rate is likely to be 
confounded, in part, by age and the type of co-morbidities. However, patients with 
heart failure or chronic kidney disease might show an excess risk and vigilance and 
further research is necessary to establish a causality link. 
(b) Neither ACE-i nor ARB are associated with greater risk of SARS-Cov2 infection, or 
severity or risk of death in patients with Covid-19. The evidence to date does not 
support the discontinuation of ACE-i or ARB. Patiens on these drugs, whether for 
high blood pressure, heart failure, coronary heart disease or renal protection in 
diabetes, should not stop them for fears related to vulnerability to Covid-19 unless 
advised by a doctor and under strict medical supervision and with the addition of a 
suitable replacement medicine. These conclusions are concordant with International 
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TABLE 1. Prevalence of hypertension and diabetes, and severity and outcomes buy 
comorbidity, in hospitalised patients with confirmed Covid-19. 
 
TABLE 2. Published evidence (as to May 12, 2020) addressing the suggestions that the use 
of ACE-inhibitors and ARBs might be harmful in the context of SARS-CoV-2 susceptibility 
to infection and in the prognosis of patients with Covid-19. 
 
FIGURE 1. Schematic interaction between the renin-angiotensin-aldosterone system and 
SARS-CoV-2. On the left side the role of circulating ACE and ACE2 in the cleavage of 
angiotensin polypeptides and the site of actions of ACE-inhibitors and ARBs. On the right 
the binding of SARS-CoV-2 spike proteins to membrane-bound ACE2 that allows the virus 
to enter the cell (endocytosis) and replicate. Blockade of the AT1R by ARB will increase Ang 
II circulating levels that will shed the membrane-bound ACE2 resulting in an increase in the 





















Not severe vs 
Severe (%) 
Chen N6 (China) 99 55.6 40.0* 13.0     
Chen T7 (China) 274 68.0 34.0 17.0 24.0 vs 48.0  14.0 vs 21.0  
Conversano11 (Italy) 191 63.4 50.2 14.6 42.3 vs 81.0  11.4 vs 26.2  
Guan2 (China) 1,099 47.0 15.0 7.4 13.7 vs 35.8 13.4 vs 23.7 6.1 vs 26.9 5.7 vs 16.2 
Guo8 (China) 187 58.5 32.6 15.0     
Li9 (China) 1,178 55.5 30.7 n/a     
Mancia10 (Italy) 6,272 68.0 57.9^ 19.1^     
Mehra12 (Global) 8,910 49.0 26.3 14.3 26.4 vs 25.2  14.0 vs 18.8  
Mehta13 (USA) 1,735 49.0 78.6 38.2     
Meng14 (China) 417 64.5 12.2 n/a     
Reynolds15 (USA) 12,594 49.0 34.6 18.0     
Richardson5 (USA) 5,700 63.0 56.6 33.8     
Shi16 (China) 416 64.0 30.5 14.4     
Wang17 (China) 138 56.0 31.2 10.1  21.6 vs 58.3  5.9 vs 22.2 
Yang18 (China) 52 51.9 n/a 17.0    10.0 vs 22.0 
Zhang19 (China) 140 57.0 30.0 12.1  24.4 vs 37.9  13.8 vs 11.0 
Zhou20 (China) 191 56.0 30.0 19.0 23.0 vs 48.0  14.0 vs 31.0  
Zhu21 (China) 7,337 62 24.0 12.9   2.7 vs 7.8  




TABLE 2.  
Author 
(Country) 








Acute inpatients with 
Covid-19 at King's 
College Hospital and 
Princess Royal University 
Hospital in London. Mean 
age 63 yrs; 52% men; 
51.2% with hypertension. 
Case-series (n=205) 
followed-up for 7-days 
from symptoms onset to 
primary end point 
(death or transfer to 
ICU). 53 patients 
reached end-point. 
Lower death rate or transfer to ICU within 7 
days in patients on an ACE-i (OR 0.29, 95% CI 
0.10 to 0.75, p<0.01), adjusting for age, gender, 
comorbidities (hypertension, diabetes mellitus, 
ischaemic heart disease and heart failure). 
- 
No evidence for ACE-i 
increasing the short-term 
severity of Covid-19 
disease. 








Patients admitted to San 
Raffaele Hospital in Milan 
with confirmed SARS-
CoV-2 pneumonia. Mean 
age: 63.4 yrs; 68.6% men. 
Retrospective case-
series (n=191), 96 
(50.2%) with 
hypertension 
Predictors of death in Cox models (HR, 95% 
CI). 
All (n=191): Age (1.1, 1.0-1.2); HF (3.1, 1.3-
7.5); CKD (2.1, 1.1-4.0). 
Hypertensive (n=96): Age 1.1 (1.0-1.1); HF 2.8 
(1.1-6.9). 
No association 
between use of ACE-
i/ARB with mortality 
in both group in 
multivariate models. 
In a multivariate model, 
age, heart failure and CKD 
(but not hypertension, 
diabetes and current use of 
ACE-i/ARB) were 
independent predictors of 
mortality. 
[1] Multivariate models deal with 
important confounders. [2] Small 







Hospitalised patients with 
Covid-19 infections at the 
Seventh Hospital of 
Wuhan City. Mean age 
58.5 yrs; 48.7% men. 
Retrospective case 




Death rates with and 
without use of ACE-
i/ARB 36.8% (7/19) 
and 25.6% (43/168), 
respectively. 
Not primary objective of 
the study.  
[1] Incidental finding. [2] Small 








Hospitalised patients with 
Covid-19 infections at the 
Central Hospital of 
Wuhan. Median age 55.5 
yrs; 46.3% men. 
Retrospective case 
series (n=1,178),  
362 (30.7%) with 
hypertension. 
In-hospital mortality 21.3%. Percentage taking 
ACE-i/ARB did not differ between those with 
severe and non-severe infections (32.9% vs 
30.7%; P=0.645) nor did it differ between non-
survivors and survivors (27.3% vs 33.0%; 
P=0.34). 
Similar findings when 
data analysed for 
patients taking ACE-i 
and ARB. 
ACE-i/ARB not associated 
with severity or mortality 




[1] Small number of patients with 
hypertension taking ACE-i/ARB who 
were hospitalized with Covid-19. [2] 
Not generalisable to all patients with 








Residents in Lombardy, 
40+ years, beneficiaries of 
the Regional Health 
Service as target 
population (>6M, ~17% 
of the Italian population 
of that age). Mean age 68 
yrs; 37% women. 
Population-based case-
control study (6,272 





matched by age, sex and 
municipality. 
[1] Use of ARBs or ACE inhibitors did not 
show association with Covid-19 among case 
patients overall (adjusted OR 0.95, 95% CI: 
0.86 to 1.05) for ARB and 0.96, 0.87 to 1.07) 
for ACE-i or among patients who had a severe 
or fatal course of the disease (adjusted OR 0.83, 
0.63 to 1.10) for ARB and 0.91, 0.69 to 1.21 for 
ACE-i. [2] No association according to sex. 
[1] Use of ACE-i and 
ARBs more frequent 
among patients with 
Covid-19 than 
controls. [2] Results 
apply to both sexes, 
younger and older. [3] 
Loop diuretics 
associated with an 
increased risk of 
Covid-19. 
No evidence that ACE-i or 
ARB affect the risk of 
Covid-19 or its severity. 
[1] Large sample size, well-matched 
controls. [2] Drugs prescribed to 
outpatients accurately recorded. [3] 
Information on drug use limited to 
prescriptions, not actual consumption. 
[4] Drugs purchased by the patients and 
those dispensed after Dec 31, 2019, not 













Patients with Covid-19 
hospitalised in 169 
hospitals in 3 continents.  
Observational database 
(n=8,910), 1,536 from 
N America, 5,755 from 
Europe and 1,619 from 
Asia). 
515 died and 8,395 survived to discharge. No 
increased risk of in-hospital death associated 
with the use of ACE-i (2.1% vs. 6.1%; OR 0.33; 
95% CI, 0.20 to 0.54) or ARBs (6.8% vs. 5.7%; 
OR 1.23; 0.87 to 1.74). 





increased risk of in-
hospital death. 
Results did not confirm 
concerns regarding a 
potential harmful 
association of ACE-I or 
ARB with in-hospital 
death. 
[1] Large sample size. [2] International 
representation of patients.  
[1] Cannot exclude confounding. [2] 
No pre-specified hypothesis, hence 
increased probability of chance finding. 
[3] Cause-effect relationship between 









All patients tested for 
SARS-CoV-2 at the 
Cleveland Clinic Health 
System in Ohio and 
Florida. Mean age 49 yrs; 
40% men; 69% white.  
Retrospective cohort 
analysis (n=18,472), 
2,285 taking either 
ACE-i or ARB, with 
overlap propensity 
score (OPS) weighting. 
OPS weighting showed no significant 
association of ACE-i and/or ARB use with 
SARS-CoV-2 test positivity (OPS–weighted OR 
0.97; 95%CI, 0.81-1.15). For use of ACE-i only, 
OPS–weighted OR 0.89; 0.72-1.10.  
Higher likelihood of 
hospital admission in 
patients with positive 
results who were 
taking either ACE-
i/ARB (OR 1.84; 1.22-
2.79), or ACEIs only 
(OR 1.77; 1.07-2.92). 
No association between 
ACE-i or ARB use and 
SARS-CoV-2 test 
positivity. 
[1] Risk of confounding. [2] No 
information on duration of drug use 
before and after testing. [3] Data reflect 
medication list in the electronic medical 
record, not actual use, risk of non-
ascertainment bias. [4] most patients 
white, limited generalisability to other 
ethnic groups. [5] Small sample size 








Covid-19 patients with 
treated hypertension. 
Median age 64.5 yrs; 57% 
men. 
Retrospective review of 
medical records (n=42 
out of 417) admitted  to 
Hospital in the period. 
During hospitalisation, 12 patients in the non 
ACE-i/ARB group (48%) were severe and one 
died. In contrast, in the ACE-i/ARB group only 
4 patients (23.5%) were severe and none died. 
ACE-i and ARB 
associated with 
increased CD3 and 
CD8 T cell counts and 
lower peak viral load. 
Patient receiving ACE-i or 
ARB had lower rate of 
severe diseases. 
[1] Observational case-series. [2] Small 







All the patients in the 
New York University 
(NYU) Langone Health 
electronic health record 
who had Covid-19 test 
results recorded. 
Observational study 
using Electronic Health 
Records (n=12,594), 
5,894 with positive test 
and 1,002 with severe 
illness (defined as 
admission to ICU, 
mechanical ventilation 
or death). 
[1] Among 12,594 patients, 4,357 (34.6%) had 
hypertension; of these, 2,573 (59.1%) were 
Covid-19–positive and 1,784 (40.9%) were 
Covid-19–negative. The results in matched 
patients ruled out an absolute difference of 
>10% in the likelihood of a positive test with at 
least 97.5% certainty for ACE inhibitors, ARBs, 
beta-blockers, calcium-channel blockers, and 
thiazide diuretics. [2] Among the 2,573 patients 
with hypertension and positive results on Covid-
19 testing, 634 (24.6%) had severe Covid-19. 
The likelihood of severe Covid-19 among 
patients who tested positive, matched on 
propensity score for previous treatment, ruled 
out a ≥10% in the likelihood of severe illness 
with at least 97.5% certainty for all the 
medication classes. 
- 
No substantial increase in 
likelihood of a positive test 
for Covid-19 or risk of 
severe Covid-19 in patients 
who tested positive in 
association with five 
common classes of anti-
hypertensive medications, 
including ACE-i and ARB. 
[1] Propensity-score matching creates 
balance between comparison groups. 
[2] Variations in diagnostic 
characteristics for Covid-19 testing 
methods may have led to 
misclassification of Covid-19 status. [3] 
Some patients underwent multiple tests, 
increased likelihood of identifying 
disease. [4] Possible Covid-19 are not 
tested, particularly those who are not 
hospitalised. Results may overestimate 
proportion of severe Covid-19. [5] 
Ascertainment of medication use may 







Patients admitted to 12 
hospitals in NYC, Long 
Island and Westchester 
County, within the 
Northwell Health system 
with Covid-19 confirmed 
positive to SARA-CoV-2.. 
Median age 63 yrs; 39.7% 
women; 56.6% with 
hypertension. 
Case-series (n=5,700) 
patients admitted to 
hospital. Outcomes 
assessed in 2,634 who 
were either discharged 
or died (latter n=553). 
- 
[1] Of 2,411, 189 were 
on ACE-i and 267 on 
ARBs. During 
admission, 91 and 136, 
respectively continued 
their RAAS blocker as 
in-patients. [2] Suppl. 
Tab.2. Hypertensives 
on ACE-i: died 55, 
discharged 113; on 
ARB: died 75, 
discharged 170. Not 
on ACE-i/ARB: died 
254; discharged 699. 
This case series design 
cannot address the 
complexity of this 
question. 
[1] Results are unadjusted for known 
confounders, including age, sex, race, 
ethnicity, socioeconomic status 
indicators, and comorbidities such as 
diabetes, chronic kidney disease, and 
heart failure. [2] Study population only 
included patients within the New York 
metropolitan area. [3] Electronic health 
record database. [4] Brief post-
discharge follow-up. [5] Clinical 
















Patients with hypertension 
diagnosed with Covid-19 
and admitted to 9 
hospitals in Hubei 
Province. 
Retrospective multi-
center study (n= 1,128), 
18 taking ACE-I/ARB 
and 940 not on them. 
Risk for all-cause mortality lower in the ACE-
i/ARB group vs non-ACE-i/ARB group 
(adjusted HR 0.42; 95%CI 0.19-0.92; P=0.03). 
In a propensity score-matched analysis followed 
by adjusting imbalanced variables, lower risk of 
Covid-19 mortality in patients who received 
ACE-i/ARB vs those who did not receive ACE-
i/ARB (adjusted HR 0.37; 0.15-0.89; P= 0.03). 
Compared to use of 
other antihypertensive 
drugs, ACEI/ARB was 
associated with 
decreased mortality 




Covid-19 patients with 
hypertension, inpatient use 
of ACE-i/ARB was 
associated with lower risk 
of all-cause mortality 
compared with ACE-
i/ARB non-users 
[1] May not reflect outpatient 
management. [2] Modest sample size in 
those on ACE-i/ARB. [3] Some 
parameters not available in all patients. 
[4] Antihypertensive drugs not matched 
or adjusted when comparing ACE-
i/ARB and non-ACE-i/ARB groups. [5] 
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